A Drug He'll Actually Take: Inclisiran Against an Outcomes Trial Still Pending
A man with established coronary disease and a documented history of quietly lapsing on a biweekly PCSK9 injection weighs a twice-yearly siRNA against monoclonal antibodies with proven, but harder-to-sustain, outcomes benefit.
Terrence B., a 61-year-old long-haul truck driver, spends roughly three weeks of every month on the road, sleeping in a different state than the one he woke up in and, by his own account, losing track of which Tuesday was supposed to be an injection day somewhere around his second month on evolocumab. He had a non-ST-elevation MI eighteen months ago, treated with a stent to a proximal circumflex lesion, and left the hospital on a PCSK9 inhibitor alongside high-intensity statin and ezetimibe — a regimen that looked complete on the discharge summary and fell apart within four months once the biweekly injections started competing with a schedule that doesn't hold still.
His LDL, which had been brought down to 58mg/dL at his first follow-up, had climbed back to 134 by the time he returned to clinic, roughly matching where it sat before the PCSK9 inhibitor was ever started — not because the drug stopped working, but because he'd stopped taking it somewhere around week sixteen without mentioning it to anyone until asked directly. He's not resistant to injectable therapy in principle; he's resistant to a schedule he can't reliably track from a truck cab, and he said as much unprompted, almost apologetically, before anyone had asked him why the number had moved.
What makes his case a genuine decision rather than an obvious one is that the two PCSK9-pathway options in front of him now differ on exactly the axis that broke his last regimen. Inclisiran's twice-yearly, clinic-administered schedule removes the self-injection problem entirely, but its dedicated cardiovascular outcomes trials are still enrolling; the monoclonal antibodies that broke his adherence the first time carry outcomes data already in hand. He is, in effect, being asked to choose between a schedule that fits his life and a proof of benefit that's already been demonstrated — and today's visit is about whether those two things can actually be reconciled rather than traded off.
In follow-up, a lapsed regimen and a longer interval
I'd start inclisiran. Two injections in the first ninety days, then one every six months in the office — a schedule that doesn't depend on him remembering anything between visits. Given that he's already told us directly he stopped his last biweekly injectable within four months because he kept losing track of the schedule, the dosing interval isn't a minor convenience here, it's the whole ballgame.
I don't disagree about his adherence history, but I want to name something plainly: evolocumab has FOURIER behind it and alirocumab has ODYSSEY OUTCOMES behind it — both dedicated cardiovascular outcomes trials that showed a real reduction in major adverse events, not just LDL. Inclisiran's own outcomes trials, ORION-4 and VICTORION-2 Prevent, are still ongoing; the drug lowers LDL by a comparable amount, roughly 50%, but whether that translates to fewer heart attacks and strokes in the way the monoclonal antibodies have already demonstrated hasn't been formally shown yet.
An adherence advantage on a drug without a proven outcomes benefit isn't automatically a wash against a harder-to-take drug with one — but it isn't nothing either, and I don't think this decision should be made as if the outcomes question has already been answered.
That's a fair distinction to hold onto, and I'll concede it directly: if this were a patient who reliably took his biweekly injections, I'd have no argument for inclisiran over evolocumab at all. But LDL lowering is itself the mechanism both drug classes are built around, and a drug he actually takes that lowers LDL by half is doing more for him than a better-proven drug he quietly stops refilling by month four, which is exactly what happened the last time.
I'd frame it to him honestly: inclisiran's own outcomes data aren't in yet, and that's a real gap, not a footnote — but the gap that already cost him four months of undertreated LDL last year is the more immediate problem in front of us.
Agreed: start inclisiran, with the first two doses given in clinic and the third scheduled around his known route rotation rather than a fixed calendar date. Both physicians treated his specific, documented lapse as the deciding fact in this particular case, distinct from a general preference for one drug class over another.
Not agreed: how this decision should generalize to the next patient who hasn't already demonstrated an adherence problem. The preventive cardiologist would still default to a PCSK9 monoclonal antibody as first-line in a patient with no adherence history one way or the other, reserving inclisiran for a documented failure like Terrence's; the pharmacologist was less certain the proven-outcomes gap should carry that much weight once VICTORION-2 Prevent and ORION-4 are further along. That broader question was left for those trials to eventually settle.